MAPT and supranuclear palsy, progressive, 1: Four anti-tau monoclonal antibody therapies, gosuranemab, tilavonemab, semorinemab, and zagotenemab, target epitopes N-terminal to the RD and have all failed in phase II clinical trials for either AD or PSP (32, 33, 34, 35, 36, 37, 38).